Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study

Prostate

Volumn 76, Issue 3, 2016, Pages 286-293

  Posadas, Edwin M ^a   Ahmed, Rafi S ^a   Karrison, Theodore ^b   Szmulewitz, Russell Z ^b   O'Donnell, Peter H ^b   Wade, James L ^c   Shen, James ^a   Gururajan, Murali ^a   Sievert, Margarit ^a   Stadler, Walter M ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Cancer Care Specialists of Central Illinois   (United States)

Author keywords

azd0530; castration resistant; Fyn; prostate cancer; saracatinib

Indexed keywords

DOCETAXEL; PLACEBO; SARACATINIB; 1,3 BENZODIOXOLE DERIVATIVE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG WITHDRAWAL; EDEMA; FATIGUE; FLU LIKE SYNDROME; HEMATURIA; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEAKNESS; CLINICAL TRIAL; ILLINOIS; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; CHICAGO; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUINAZOLINES;

EID: 84954394553     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23119     Document Type: Article

References (28)

1. Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Dakin-Hache K, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM,. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res 2011; 17 (10): 3112-3122.
2. Saito YD, Jensen AR, Salgia R, Posadas EM,. Fyn: A novel molecular target in cancer. Cancer 2010; 116 (7): 1629-1637.
3. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R,. FYN is overexpressed in human prostate cancer. BJU Int 2009; 103 (2): 171-177.
4. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON,. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci USA 2013; 110 (49): E4762-E4769.
5. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, Graeber TG, Witte ON,. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci USA 2012; 109 (5): 1643-1648.
6. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON,. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci USA 2011; 108 (16): 6579-6584.
7. Cai H, Babic I, Wei X, Huang J, Witte ON,. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 2011; 71 (3): 862-872.
8. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, Weinstein I, Reuveni H, Ben-Sasson SA,. Lyn is a target gene for prostate cancer: Sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004; 64 (3): 1058-1066.
9. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE,. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68 (9): 3323-3333.
10. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Ple PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF,. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009; 3 (3): 248-261.
11. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ,. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (16): 2505-2512.
12. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ,. Successful implementation of the randomized discontinuation trial design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 2005; 23 (16): 3726-3732.
13. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1): 9-29.
14. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C-A-,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995-2005.
15. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Investigators A,. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-1197.
16. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, Investigators IS,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-422.
17. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators T,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376 (9747): 1147-1154.
18. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators A,. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213-223.
19. Jensen AR, Saito YD, Liao C, Dai J, Keller ET, Al-Ahmadie HA, Dakin Hache K, Usatyuk P, Sievert MF, Paner G, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM,. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res 2011; 17 (10): 3112-3122.
20. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR,. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: A California Cancer Consortium Study. Anticancer Drugs 2009; 20 (3): 179-184.
21. Aragon-Ching JB, Dahut WL,. VEGF inhibitors and prostate cancer therapy. Current Mol Pharmacol 2009; 2 (2): 161-168.
22. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD,. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14 (1): 209-214.
23. Dixon SC, Kruger EA, Bauer KS, Figg WD,. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999; 43 Suppl: S78-S84.
24. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G,. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2014; 74 (3): 297-305.
25. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ,. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 2014; 65 (1): 3-6.
26. Wang H, Li B, Zhang P, Yao Y, Chang J,. Clinical characteristics and prognostic factors of prostate cancer with liver metastases. Tumour Biol 2014; 35 (1): 595-601.
27. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM,. NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods 2013; 64 (2): 144-152.
28. Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, Ouyang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, Chung LW, Rettig M, Tseng HR, Posadas EM,. High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing. Adv Mater 2013; 25 (21): 2897-2902.